Invion Stock

Invion CROIC

Cash Return on Invested Capital (CROIC) of Invion (IVX.AX) as of Sep 3, 2026.

CROIC

0.00

Last updated:

Cash Return on Invested Capital (CROIC) of Invion is 2026 0.00 . Cash Return on Invested Capital (CROIC) of Invion was 2025 0.00 . It decreases by % lower compared to the previous year.

The Invion CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2016
-53.31 AUD
Jan 1, 2017
-4.69 AUD
Jan 1, 2018
8.92 AUD
Jan 1, 2019
-38.70 AUD
Jan 1, 2020
-2.81 AUD
Jan 1, 2021
8.73 AUD
Jan 1, 2022
-42.69 AUD
The Invion CROIC history
YEARCROICYoY
-42.69 %-589.31%
8.73 %-410.90%
-2.81 %-92.75%
-38.70 %-533.80%
8.92 %-290.04%
-4.69 %-91.19%
-53.31 %—
Access this data via the Eulerpool API
Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Invion since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Invion

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Invion